Compare GP & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GP | BRTX |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.3M |
| IPO Year | 2013 | 2015 |
| Metric | GP | BRTX |
|---|---|---|
| Price | $1.12 | $0.20 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 02-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.19 |
| 52 Week High | $4.00 | $2.04 |
| Indicator | GP | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 36.58 |
| Support Level | $0.88 | $0.20 |
| Resistance Level | $1.12 | $0.30 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 74.99 | 10.52 |
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.